Media : Press Room
Press Room : Press Releases
For Immediate Release: November 20, 2008
Eisai Inc. Joins Venous Disease Coalition
The Venous Disease Coalition (VDC) announced today that Eisai Inc. has joined the VDC as a national Platinum/Founding Sponsor supporting efforts to fight deadly blood clots known as deep vein thrombosis (DVT) and its complication, pulmonary embolism (PE). DVT and PE affect hundreds of thousands of Americans each year.
Eisai supported the VDC at its recent second annual meeting where Acting Surgeon General Rear Admiral Steven K. Galson issued “The Surgeon General’s Call to Action for the Prevention of Deep Vein Thrombosis and Pulmonary Embolism,” which urged all Americans to learn about these preventable and treatable conditions. As a national sponsor, Eisai will continue to support the VDC in its efforts to educate the general public and health care professionals about DVT and PE as well as help to create a national educational awareness campaign for the general public.
"Hundreds of thousands of Americans develop deep vein thrombosis and pulmonary embolism each year, underscoring the need for greater awareness of VTE," said Cynthia Schwalm, President, Eisai Inc. "We are pleased to support the Venous Disease Coalition’s efforts to educate both patients and healthcare professionals about this potentially life-threatening condition.”
DVT is the formation of a blood clot in a deep vein, usually in the leg, that can be fatal when the clot breaks free and travels through the heart and into the lungs, causing a complication called PE. Major risk factors for DVT include recent major surgery, cancer and its treatment, major trauma or injuries to the leg, previous DVT or PE, hospitalization with an acute illness, pregnancy, use of birth control or hormone replacement therapy, family history of DVT or PE, and obesity.
“We are very pleased with Eisai’s support and contribution to the VDC,” said Samuel Z. Goldhaber, MD, President of the VDC. “Eisai shares the same goal as the VDC, to help educate as many people as possible about these deadly, yet preventable and treatable diseases.”
About Eisai Inc.
Eisai Inc. is a U.S. pharmaceutical subsidiary of Eisai Co., Ltd., a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Eisai focuses its efforts in three therapeutic areas: neurology, gastrointestinal disorders and oncology/critical care. Established in 1995 and ranked among the top-20 U.S. pharmaceutical companies (based on retail sales), Eisai Inc. began marketing its first product in the United States in 1997 and has rapidly grown to become an integrated pharmaceutical business with fiscal year 2007 (year ended March 31, 2008) sales of approximately $3 billion, including the results of the acquisition of MGI PHARMA, Inc.
Eisai Inc. employs approximately 1,900 people at its headquarters in Woodcliff Lake, NJ, at its state-of-the-art pharmaceutical production and formulation research and development facility in Research Triangle Park, NC, and in the field. For more information about Eisai, please visit www.eisai.com.
About the Venous Disease Coalition
The Venous Disease Coalition (VDC) is an alliance of more than 35 leading health professional societies and patient advocacy groups that have united around a common goal: To improve the survival rates and quality of life for individuals with, or at risk for, venous disease. The VDC plans to develop a national campaign to educate public and health care professionals in the U.S. about venous disease. The VDC is supported by unrestricted educational grants from AngioDynamics Inc., BioMedix, BSN Jobst, Cook Medical, Covidien, Eisai Inc., and Juzo. It is a program of the Vascular Disease Foundation (www.vdf.org). For more information, visit www.VenousDiseaseCoalition.org.
About the Vascular Disease Foundation
The Colorado-based Vascular Disease Foundation is a national 501(c)(3) non-profit organization with the sole purpose of educating the public about vascular disease. It is the most trusted source of credible, scientific and non-biased information on vascular disease. For more information, call 888.VDF.4INFO (888.833.4463) or visit www.vdf.org.
# # #
